Turn Therapeutics Inc. Common Stock (TTRX)
StalwartFairStock Score: 28/100 — RISKY
Key Financials
| Current Price | $4.05 |
| Market Cap | $100M |
| P/E Ratio | -31.15 |
| ROE | -129.17% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Generates $2 million in annual free cash flow (1.7% yield on market cap)
- Altman Z-Score of 17.4 confirms minimal bankruptcy risk and strong solvency
Concerns
- Weak Piotroski F-Score of 0/9 suggests deteriorating financial quality across multiple dimensions
AI Analysis
Turn Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $100 million. From a quality standpoint, Turn shows weak Piotroski F-Score of 0/9 signaling deteriorating fundamentals and Altman Z-Score of 17.4 confirms fortress-level solvency. On valuation, the stock is 1.7% FCF yield. Our composite FairStock Score of 28/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $2 million in annual free cash flow (1.7% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer